| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44016608 | HTLV-1 | ENSG00000198704.10 | protein_coding | GPX6 | No | No | 257202 | P59796 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GPX6 |
|---|---|
| DrugBank ID | DB00143 |
| Drug Name | Glutathione |
| Target ID | BE0002286 |
| UniProt ID | P59796 |
| Regulation Type | cofactor |
| PubMed IDs | 17139284; 17016423; 17081103; 3532684; 17588737 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Brigelius-Flohe R: Glutathione peroxidases and redox-regulated transcription factors. Biol Chem. 2006 Oct-Nov;387(10-11):1329-35.@@Myllyla V, Kihlstrom M, Takala TE, Tolonen U, Salminen A, Vihko V: Activities of some antioxidative and hexose monophosphate shunt enzymes of skeletal muscle in neuromuscular diseases. Acta Neurol Scand. 1986 Jul;74(1):17-24.@@Giovannini C, Scazzocchio B, Matarrese P, Vari R, D'Archivio M, Di Benedetto R, Casciani S, Dessi MR, Straface E, Malorni W, Masella R: Apoptosis induced by oxidized lipids is associated with up-regulation of p66Shc in intestinal Caco-2 cells: protective effects of phenolic compounds. J Nutr Biochem. 2008 Feb;19(2):118-28. Epub 2007 Jun 27. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | Peptides |
| SMILES | N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O |
| Pathways | Arachidonic Acid Metabolism; Flurbiprofen Action Pathway; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Oxaprozin Action Pathway; Rofecoxib Action Pathway; Pyruvate Kinase Deficiency; Acetaminophen Metabolism Pathway; Mefenamic Acid Action Pathway; Bromfenac Action Pathway; 5-Oxoprolinuria; gamma-Glutamyltransferase Deficiency; Naproxen Action Pathway; Sulindac Action Pathway; Glutathione Synthetase Deficiency; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); Meloxicam Action Pathway; Cyclophosphamide Action Pathway; Succinic Semialdehyde Dehydrogenase Deficiency; Valdecoxib Action Pathway; Ketorolac Action Pathway; 5-Oxoprolinase Deficiency; Acetylsalicylic Acid Action Pathway; Antipyrine Action Pathway; Glutathione Metabolism; Diclofenac Action Pathway; Homocarnosinosis; Cyclophosphamide Metabolism Pathway; Nepafenac Action Pathway |
| PharmGKB | PA449780 |
| ChEMBL | CHEMBL1543 |
